Top Injectable Manufacturer in Equatorial Guinea – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 4 days ago
- 11 min read
Last Updated: September 4, 2026
TL;DR: Equatorial Guinea answers the question we always ask first — does the country keep a list of regulators it will rely on, and is India on it — with no list at all, because its gate is a certificate test rather than an agency test. Ley del Medicamento 3/2003 requires every imported lot to be lodged with the Ministry of Health and Social Welfare with its invoices and a quality certificate under the WHO certification scheme, or failing that the supplying laboratory's own, and forbids import or customs release without the Ministry's prior authorisation. The registry, quality-control laboratory and essential-medicines list the same law promised are written in the future tense, and we found none operating, nor any published guideline, fee, timeline or dossier format; the regulator is a directorate general inside the Ministry, not a standalone agency. India appears twice: in a Ministry resolution concerning the Indian firm named in the WHO alert of October 2022, which we could not read, and by absence from the Indian Pharmacopoeia Commission's July 2026 list of recognising countries. Equatorial Guinea has signed but not ratified the African Medicines Agency treaty and is absent from the WHO maturity list. The commercial gate is a licensed local distribution warehouse: the State buys through CENTRAMED, named private distributors source largely through Spain, and the Prime Minister reported in December 2024 that more than 1,500 million CFA francs of government medicines were expiring in the central warehouses.
Key Takeaways
A certificate test, not an agency test. Article 18 of Ley 3/2003 requires distribution warehouses to lodge, for each imported lot, the invoices and a quality certificate according to the scheme established by the WHO, or failing that the supplying laboratory's own certificate; Article 19 bars import or customs release without prior Ministry authorisation; Article 3 allows only Ministry-authorised products on the market. No reference-authority list exists to be on or off, and no country-of-origin rule was found.
A law but not yet a visible regulator. The regulator is the Directorate General for Supply, Pharmacy, Biomedical Laboratories and Blood Bank within the Ministry; no standalone agency exists. The registry, quality-control laboratory and essential-medicines list that Article 6 says will be created could not be found in operation; dossier format, fees, timelines, validity and sample rules are all unpublished. Article 5 admits a new medicine only if it offers an advantage over a similar product already authorised, and Article 61 sends suspect lots to a reference laboratory of the subregion.
India is mentioned, but not in a way we can read. The Ministry's legal-documents page lists a ministerial resolution concerning Maiden Pharmaceuticals, the Indian company named in the WHO alert of October 2022; the file is a scanned image without readable text, so we do not characterise its scope or whether it remains in force. The Indian Pharmacopoeia Commission's recognition list of 10 July 2026 does not include Equatorial Guinea, although two Ministry officers attended the commission's policymakers' forum in August 2024. Equatorial Guinea is absent from the WHO's maturity list, on which India's CDSCO is level 3 for vaccines only.
The buyer is a licensed warehouse, and the State's own is under scrutiny. Articles 15 to 17 reserve import, distribution and sale to Ministry-authorised distribution warehouses with a pharmacist as technical director and, under Article 22, minimum capital of 50 million CFA francs. CENTRAMED is the state purchasing centre, and the Ministry names COFARMA, SANTIFARMA, GEFARMA, GLOBALFARMA and MUNDOFARMA as the private distributors it relies on. In December 2024 the Prime Minister inspected CENTRAMED, found expired stock and inadequate cold rooms, and put the value of expiring government medicines above 1,500 million CFA francs. Out-of-pocket payments were 66% of health spending in 2023.
Introduction: Why Equatorial Guinea Demands a Premium Injectable Manufacturer in Equatorial Guinea
Every market in this series opens with the same question: does the country publish a list of regulatory authorities whose decisions it will lean on, and is India's CDSCO among them? Equatorial Guinea is the clearest case yet of a market where the question has no object, because the law does not gate on who approved a medicine but on what paper travels with each consignment. The statute is Ley del Medicamento 3/2003 of 18 November 2003, published in the official gazette, which repealed a decree of 1991 and came into force a year after publication; we read it in full and found no reference to reference countries, stringent authorities or reliance. Article 18 requires the licensed distribution warehouses to lodge with the Ministry of Health and Social Welfare, for each imported lot, the corresponding invoices and quality certificates according to the scheme established by the WHO — the WHO certification scheme for products moving in international commerce — or, failing that, the supplying laboratory's own, which may be a single certificate per laboratory. Article 19 provides that nothing covered by the law may be imported or released from customs without the prior authorisation of the competent Ministry services, and Article 3 that only products the Ministry has authorised may be sold.
So the honest answer is that there is no list, and that a WHO-format certificate of a pharmaceutical product is the document that matters. The harder question is who examines it. The 2023 organisation chart of the Ministry lists seven directorates general, and the one with the mandate is the Directorate General for Supply, Pharmacy, Biomedical Laboratories and Blood Bank; there is no separate regulatory agency, and the widely repeated reference to a Law 1/2000 on pharmaceutical products could not be found in any legal database, so we treat Ley 3/2003 as the law in force. That law establishes marketing authorisation and pharmaceutical registration at the Ministry, but says that a quality-control laboratory and an authorised essential-medicines list will be created, in the future tense, and we found neither a public register of authorised products nor any registration guideline, application form, fee schedule, timeline, validity period, sample rule or prescribed dossier format. A premium injectable manufacturer in Equatorial Guinea is therefore one that can supply, for every lot, the WHO-scheme certificate, the batch documentation and the stability evidence that a small directorate can examine without a laboratory of its own.
What Sets a World-Class Injectable Manufacturer in Equatorial Guinea Apart
The market structure is written into the statute. Articles 15 to 17 reserve import, distribution and sale of medicines to distribution warehouses authorised by the Ministry, which alone may supply pharmacies and health centres; Article 22 conditions a warehouse licence on, among other things, presidential authorisation for foreign investment, tax and criminal-record certificates, plans of the premises and minimum capital of 50 million CFA francs, and every warehouse must have a pharmacist as technical director. Article 45 allows the Ministry to authorise pharmacy-level import only for specialities not available in the country. Article 5 sets the authorisation criteria, including reasonable cost, and adds that a new medicine may be added only if it represents an advantage over a similar product already authorised — a formal preference for what is already on the market that a new entrant must argue against. Article 8 tiers products by the level of facility, from health post to hospital, and Article 14 requires local manufacturers to follow WHO good manufacturing practice. Every document we read, from the law to the ministerial orders to the organisation chart, is in Spanish.
India appears in this record in two places, and both deserve care. The Ministry's page of legal documents lists a ministerial resolution concerning the case of Maiden Pharmaceuticals, the Indian manufacturer named in the WHO product alert of October 2022; the linked file is a scanned image with no machine-readable text, so we could not establish what it orders, whom it covers or whether it remains in force, and we do not describe it as a ban, a restriction or as lifted. Separately, the Indian Pharmacopoeia Commission's list of countries recognising the Indian Pharmacopoeia, updated on 10 July 2026, does not include Equatorial Guinea, although two senior Ministry officers attended the commission's policymakers' forum in August 2024 — attendance, not recognition. Beyond India, the regional layer is CEMAC, the Central African Economic and Monetary Community: its heads of state adopted a common pharmaceutical policy in June 2013 and charged its health agency OCEAC with harmonising national policies, and OCEAC ran a joint marketing-authorisation assessment workshop in Brazzaville from 8 to 12 December 2025 with pharmacy experts from all six member states, at which fewer than fifteen dossiers were assessed. Equatorial Guinea's delegation was not separately named, and in the draft protocol for a CEMAC pooled-purchasing mechanism the cell naming each state's central purchasing agency is filled for five states and blank for Equatorial Guinea.
Quality Systems Behind Every Injectable Supplied to Equatorial Guinea
For a sterile injectable the evidence any assessor or inspector expects is the same: aseptic process simulation records for the ISO Class 5 filling line, environmental monitoring trends, container-closure integrity, sterility and bacterial endotoxin testing by LAL, particulate matter, validated HPLC and GC assay and impurity methods, and ICH Q1A and Q1B stability data for a hot, humid equatorial climate rather than data extrapolated from elsewhere. Because Article 61 of the law directs suspect lots to a reference laboratory of the subregion and no national quality-control laboratory is identified as operational, the certificate of analysis for each batch should be written to be reproduced by an outside laboratory, with methods that a modest facility can run, and the WHO-scheme certificate should travel with every lot, not just the first.
The international layers are quickly stated. Equatorial Guinea does not appear on the WHO's August 2026 list of authorities at maturity level 3 or 4, and no published benchmarking result for it was found; India's CDSCO appears on that list for vaccines only, so a generic clause admitting products approved by a level-3 authority would not carry a small-molecule injectable from India — we found no such clause here, and note it only so that a buyer reads any future CEMAC or national reliance provision with the scope column of the WHO list in hand. No PIC/S membership or applicant status was found for Equatorial Guinea. On the African Union's treaty status list of 22 May 2026, Equatorial Guinea signed the treaty establishing the African Medicines Agency on 2 February 2022 and has not ratified or deposited it. The harmonisation programme's country page for Equatorial Guinea exists but is empty.
Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry.
Why Farbe Firma is the Trusted Injectable Manufacturer in Equatorial Guinea for Global Buyers
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than thirty countries, including Spanish- and French-speaking markets in Africa. We build dossiers in CTD and ACTD format, which is the structure the CEMAC harmonisation work is reported to adopt and the one any future national guideline is likely to follow, and we supply the WHO-format certificate of a pharmaceutical product, the manufacturing licence and the GMP certificate as a matter of course — which, under Article 18, is precisely the paper a licensed distribution warehouse must lodge with the Ministry for each lot. Because the law reserves import to authorised warehouses, our route is through a licensed Equatoguinean distributor, with Spanish-language labelling and documentation prepared at source.
The bilateral relationship is larger than the market suggests, and it runs on oil. The Ministry of External Affairs brief of February 2026 records bilateral trade of USD 463.32 million in 2024–25, with Indian exports of USD 19.18 million and imports of USD 444.14 million, mainly oil, gas, metal scrap and timber; the total peaked at USD 983.80 million in 2019–20. The brief names pharmaceuticals explicitly among India's exports, alongside food products, cereals, meat, machinery and apparel. The only health-adjacent instrument is a memorandum on cooperation in medicinal plants approved in May 2018; there is no health memorandum, no regulator-to-regulator agreement and no Indian line of credit. What there is instead is a record of medicines as diplomacy: India handed over about 10,000 kilograms of antiretrovirals and HIV diagnostic kits to the Minister of Health on 11 February 2025, anti-tuberculosis medicines in May 2022 and COVID-19 supplies in June 2020, and the first foreign-office consultations were held in Malabo on 10 February 2025, following the state visits of 2018 in both directions. UN Comtrade returned nothing usable for the pharmaceutical trade between the two countries, so no figure is published here.
Where the money is: Equatorial Guinea has 1.94 million people, gross national income per capita of USD 5,890 in 2025, down from USD 6,050 the year before, current health expenditure of about USD 234 per person and 3.5% of GDP in 2023, and life expectancy of 63.9 years. Out-of-pocket payments were 66% of health expenditure in 2023, so the private channel is large: the Ministry names COFARMA, SANTIFARMA, GEFARMA, GLOBALFARMA and MUNDOFARMA as the distributors it relies on, and one of them runs a purchasing centre in Valencia, Spain, supplies more than 400 pharmacies and the La Paz hospitals in Malabo and Bata, and describes its products as meeting European legislation — the sourcing default an Indian supplier must displace on documentation and price. The public channel is CENTRAMED, the Central de Compras de Medicamentos, which the Ministry stresses is not the country's only supplier; in December 2024 the Prime Minister inspected its warehouses, found expired stock and inadequate cold rooms, and put the value of expiring government medicines above 1,500 million CFA francs. A programme financed by the Government and the United States Department of Justice procured more than 100 tonnes of essential medicines for all nineteen health districts between 2021 and its scheduled close in 2025, and Equatorial Guinea is on the Global Fund's 2026 eligibility list for HIV, tuberculosis and malaria. Tuberculosis incidence was 199 per 100,000 in 2024 and malaria incidence 228 per 1,000 people at risk; the country is served through Malabo on Bioko island and Bata on the mainland, with Annobón reached by air.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is India on Equatorial Guinea's list of recognised regulatory authorities?
There is no list. Ley del Medicamento 3/2003 gates on documents, not on the approving agency: each imported lot must be lodged with the Ministry with its invoices and a quality certificate under the WHO certification scheme, or failing that the laboratory's own, and nothing may be imported or cleared through customs without prior Ministry authorisation. No country-of-origin rule was found. The Ministry does publish a resolution concerning the Indian firm Maiden Pharmaceuticals, which we could not read, and the Indian Pharmacopoeia is not on the commission's July 2026 recognition list. We neither claim nor deny that CDSCO approval carries weight.
What law governs medicine registration in Equatorial Guinea?
Ley del Medicamento 3/2003 of 18 November 2003, in Spanish, which repealed the 1991 decree. It places marketing authorisation and pharmaceutical registration at the Ministry of Health and Social Welfare, admits a new medicine only if it offers an advantage over a similar one already authorised, requires local manufacturers to follow WHO GMP, and reserves import and distribution to licensed warehouses. The registry, quality-control laboratory and essential-medicines list it announces are written in the future tense, and no dossier format, fee, timeline or validity period is published.
Who is the regulator?
The Directorate General for Supply, Pharmacy, Biomedical Laboratories and Blood Bank within the Ministry of Health and Social Welfare; there is no standalone medicines agency. Equatorial Guinea is absent from the WHO maturity-level list, has signed but not ratified the African Medicines Agency treaty, and belongs to CEMAC, whose health agency ran joint marketing-authorisation assessments in Brazzaville in December 2025 with experts from all six member states; whether Equatorial Guinea's own products or agencies take part in the CEMAC joint procedures was not confirmed.
Who buys injectables in Equatorial Guinea?
Licensed distribution warehouses, which the law makes the only lawful importers. The State buys through CENTRAMED, the Central de Compras de Medicamentos, and the Ministry names COFARMA, SANTIFARMA, GEFARMA, GLOBALFARMA and MUNDOFARMA as the private distributors it relies on, several sourcing through Spain. Out-of-pocket payments are 66% of health spending. In December 2024 the Prime Minister reported more than 1,500 million CFA francs of government medicines expiring in CENTRAMED warehouses, so reliable cold-chain documentation and realistic shelf life are commercial arguments here, not formalities.
Does Farbe Firma have experience with CEMAC and Spanish-speaking markets?
Yes. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries, including Spanish- and French-speaking Africa. We prepare dossiers in CTD and ACTD format, supply the WHO-format CPP, manufacturing licence and GMP certificate for every lot, and work through licensed local distributors with Spanish-language documentation. Write to director@farbefirma.org with the product list and we will prepare the warehouse file.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments